Arrowpoint Investment Partners (Singapore) Pte. Ltd. Argenx Se Put Options Transaction History

Arrowpoint Investment Partners (Singapore) Pte. Ltd.

$113 Billion
Q2 2025

Put Options

2 transactions

Quarter	Operation	Price Per put	puts change	puts Held	SEC Form
Q1 2025 May 12, 2025	SELL	$571.0 - $671.75 $114,200 - $134,350	-200 Reduced 11.11%	1,600 $947 Million
Q4 2024 Feb 14, 2025	BUY	$520.52 - $638.33 $936,936 - $1.15 Million	1,800 New	1,800 $1.11 Billion

Others Institutions Holding ARGX

# of Institutions

492

Shares Held

28.2M

Call Options Held

370K

Put Options Held

211K

Price T Rowe Associates Inc Baltimore, MD

4.98M
Shares

$3.98 Billion
0.31% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

2.79M
Shares

$2.23 Billion
2.84% of portfolio
Janus Henderson Group PLC London, X0

2.57M
Shares

$2.05 Billion
0.73% of portfolio
Capital World Investors Los Angeles, CA

1.95M
Shares

$1.56 Billion
0.16% of portfolio
Avoro Capital Advisors LLC New York, NY

1.18M
Shares

$939 Million
11.81% of portfolio

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $44.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowpoint Investment Partners (Singapore) Pte. Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Arrowpoint Investment Partners (Singapore) Pte. Ltd. with notifications on news.

Account